Echocardiographic and clinical features of patients developing prosthesis-patient mismatch after TAVR: insights from the Recovery TAVR registry.


Journal

American heart journal
ISSN: 1097-6744
Titre abrégé: Am Heart J
Pays: United States
ID NLM: 0370465

Informations de publication

Date de publication:
03 Jun 2024
Historique:
received: 11 12 2023
revised: 26 05 2024
accepted: 27 05 2024
medline: 6 6 2024
pubmed: 6 6 2024
entrez: 5 6 2024
Statut: aheadofprint

Résumé

The impact of prosthesis-patient mismatch (PPM) on major endpoints after transcatheter aortic valve replacement (TAVR) is controversial and the effects on progression of heart damage are poorly investigated. Therefore, our study aims to evaluate the prevalence and predictors of PPM in a "real world" cohort of patients at intermediate and low surgical risk, its impact on mortality and the clinical-echocardiographic progression of heart damage. 963 patients who underwent TAVR procedure between 2017 and 2021, from the RECOVERY-TAVR international multicenter observational registry, were included in this analysis. Multiparametric echocardiographic data of these patients were analyzed at 1-year follow-up (FU). Clinical and echocardiographic features were stratified by presence of PPM and PPM severity, as per the most current international recommendations, using VARC-3 criteria. 18% of patients developed post-TAVR. PPM, and 7.7% of the whole cohort had severe PPM. At baseline, 50.3% of patients with PPM were male (vs 46.2% in the cohort without PPM, p=0.33), aged 82 (IQR 79-85y) years vs 82 (IQR 78-86 p=0.46), and 55.6% had Balloon-Expandable valves implanted (vs 46.8% of patients without PPM, p=0.04); they had smaller left ventricular outflow tract (LVOT) diameter (20 mm, IQR 19-21 vs 20 mm, IQR 20-22, p=0.02), reduced SVi (34.2 vs 38 ml/m PPM was observed in 18% of patients undergoing TAVR. Echocardiographic evaluations demonstrated a PPM-related pattern of early ventricular maladaptive alterations, possibly precursor to a reduction in cardiac function, associated with a significant deterioration in NYHA class at 1 year. These findings emphasize the importance of prevention of PPM of any grade in patients undergoing TAVR procedure, especially in populations at risk.

Sections du résumé

BACKGROUND BACKGROUND
The impact of prosthesis-patient mismatch (PPM) on major endpoints after transcatheter aortic valve replacement (TAVR) is controversial and the effects on progression of heart damage are poorly investigated. Therefore, our study aims to evaluate the prevalence and predictors of PPM in a "real world" cohort of patients at intermediate and low surgical risk, its impact on mortality and the clinical-echocardiographic progression of heart damage.
METHODS METHODS
963 patients who underwent TAVR procedure between 2017 and 2021, from the RECOVERY-TAVR international multicenter observational registry, were included in this analysis. Multiparametric echocardiographic data of these patients were analyzed at 1-year follow-up (FU). Clinical and echocardiographic features were stratified by presence of PPM and PPM severity, as per the most current international recommendations, using VARC-3 criteria.
RESULTS RESULTS
18% of patients developed post-TAVR. PPM, and 7.7% of the whole cohort had severe PPM. At baseline, 50.3% of patients with PPM were male (vs 46.2% in the cohort without PPM, p=0.33), aged 82 (IQR 79-85y) years vs 82 (IQR 78-86 p=0.46), and 55.6% had Balloon-Expandable valves implanted (vs 46.8% of patients without PPM, p=0.04); they had smaller left ventricular outflow tract (LVOT) diameter (20 mm, IQR 19-21 vs 20 mm, IQR 20-22, p=0.02), reduced SVi (34.2 vs 38 ml/m
CONCLUSIONS CONCLUSIONS
PPM was observed in 18% of patients undergoing TAVR. Echocardiographic evaluations demonstrated a PPM-related pattern of early ventricular maladaptive alterations, possibly precursor to a reduction in cardiac function, associated with a significant deterioration in NYHA class at 1 year. These findings emphasize the importance of prevention of PPM of any grade in patients undergoing TAVR procedure, especially in populations at risk.

Identifiants

pubmed: 38838970
pii: S0002-8703(24)00137-6
doi: 10.1016/j.ahj.2024.05.015
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Ltd. All rights reserved.

Auteurs

Francesco Bruno (F)

Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Joao Matteo Rampone (JM)

Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Fabian Islas (F)

Hospital Clínico San Carlos, IDISSC, and Universidad Complutense de Madrid, Madrid, Spain.

Riccardo Gorla (R)

Department of Clinical and Interventional Cardiology, IRCCS Policlinico San Donato, Milan, Italy.

Guglielmo Gallone (G)

Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Francesco Melillo (F)

IRCCS San Raffaele Hospital, Milan, Italy.

Pier Pasquale Leone (PP)

IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy.

Paolo Cimaglia (P)

GVM Care and Research, Maria Cecilia Hospital, Ravenna, Italy.

Maria Concetta Pastore (MC)

Azienda Ospedaliero Universitaria "Maggiore Della Carita", Novara, Italy.

Anna Franzone (A)

Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Federico Landra (F)

Department of Cardiovascular Diseases, University of Siena, Policlinico "Le Scotte", Viale Bracci 1, 53100 Siena, Italy.

Luca Scudeler (L)

Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Pilar Jimenez-Quevedo (P)

Hospital Clínico San Carlos, IDISSC, and Universidad Complutense de Madrid, Madrid, Spain.

Tommaso Viva (T)

Department of Clinical and Interventional Cardiology, IRCCS Policlinico San Donato, Milan, Italy.

Francesco Piroli (F)

IRCCS San Raffaele Hospital, Milan, Italy.

Renato Bragato (R)

IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy.

Michele Trichilo (M)

GVM Care and Research, Maria Cecilia Hospital, Ravenna, Italy.

Anna Degiovanni (A)

Azienda Ospedaliero Universitaria "Maggiore Della Carita", Novara, Italy.

Stefano Salizzoni (S)

Division of Cardiac Surgery, Cardiovascular and Thoracic Department, Città Della Salute e Della Scienza Hospital and University of Turin, Turin, Italy.

Federica Ilardi (F)

Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Alessandro Andreis (A)

Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Luis Nombela-Franco (L)

Hospital Clínico San Carlos, IDISSC, and Universidad Complutense de Madrid, Madrid, Spain.

Maurizio Tusa (M)

Department of Clinical and Interventional Cardiology, IRCCS Policlinico San Donato, Milan, Italy.

Marco Toselli (M)

GVM Care and Research, Maria Cecilia Hospital, Ravenna, Italy.

Federico Conrotto (F)

Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Matteo Montorfano (M)

IRCCS San Raffaele Hospital, Milan, Italy.

Rachele Manzo (R)

Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Matteo Cameli (M)

Department of Cardiovascular Diseases, University of Siena, Policlinico "Le Scotte", Viale Bracci 1, 53100 Siena, Italy.

Giuseppe Patti (G)

Azienda Ospedaliero Universitaria "Maggiore Della Carita", Novara, Italy.

Giulio Stefanini (G)

IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy.

Luca Testa (L)

Department of Clinical and Interventional Cardiology, IRCCS Policlinico San Donato, Milan, Italy.

Michele La Torre (M)

Division of Cardiac Surgery, Cardiovascular and Thoracic Department, Città Della Salute e Della Scienza Hospital and University of Turin, Turin, Italy.

Francesco Giannini (F)

GVM Care and Research, Maria Cecilia Hospital, Ravenna, Italy.

Eustachio Agricola (E)

IRCCS San Raffaele Hospital, Milan, Italy.

Javier Escaned (J)

Hospital Clínico San Carlos, IDISSC, and Universidad Complutense de Madrid, Madrid, Spain.

Ovidio De Filippo (O)

Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza, University of Turin, Turin, Italy. Electronic address: ovidio.defilippo@gmail.com.

Gaetano M De Ferrari (GM)

Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Fabrizio D'Ascenzo (F)

Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza, University of Turin, Turin, Italy.

Classifications MeSH